Microarray gene expression profiling reveals antioxidant-like effects of angiotensin II inhibition in atherosclerosis

Frontiers in Physiology

Volumn 4 JUN, Issue , 2013, Pages

  Alla, Joshua Abd ^a   Faramawy, Yasserel ^a   Quitterer, Ursula ^a,b  

^a ETH ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Angiotensin II; Angiotensin converting enzyme; Atherosclerosis; Captopril; Neuroprotection; Oxidative stress; Perivascular nerve; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; APOLIPOPROTEIN E; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; NEUROPEPTIDE Y; REACTIVE OXYGEN METABOLITE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; AORTA INTIMA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; MICROARRAY ANALYSIS; MOUSE; NERVE DEGENERATION; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UPREGULATION;

EID: 84884567893     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2013.00148     Document Type: Article

References (47)

1. Abd Alla, J., Langer, A., Elzahwy, S. S., Arman-Kalcek, G., Streichert, T., and Quitterer, U. (2010). Angiotensin-converting enzyme inhibition down-regulates the pro-atherogenic chemokine receptor 9 (CCR9)-chemokine ligand 25 (CCL25) axis. J. Biol. Chem. 285, 23496-23505. doi: 10.1074/jbc.M110.117481
2. Abd Alla, S., Lother, H., Langer, A., el Faramawy, Y., and Quitterer, U. (2004). Factor XIIIA transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of atherosclerosis. Cell 119, 343-354. doi: 10.1016/j.cell.2004.10.006
3. Bevan, R. D. (1984). Trophic effects of peripheral adrenergic nerves on vascular structure. Hypertension 6, III19-III26. doi: 10.1161/01.HYP.6.6_Pt_2.III19
4. Cassis, L. A., Rateri, D. L., Lu, H., and Daugherty, A. (2007). Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler. Thromb. Vasc. Biol. 27, 380-386. doi: 10.1161/01.ATV.0000254680.71485.92
5. Chalupsky, K., and Cai, H. (2005). Endothelial dihydrofolate reductase: critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 102, 9056-9061. doi: 10.1073/pnas.0409594102
6. Daugherty, A., Rateri, D. L., Lu, H., Inagami, T., and Cassis, L. A. (2004). Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110, 3849-3857. doi: 10.1161/01.CIR.0000150540.54220.C4
7. Denger, S., Jahn, L., Wende, P., Watson, L., Gerber, S. H., Kübler, W., et al. (1999). Expression of monocyte chemoattractant protein-1 cDNA in vascular smooth muscle cells: induction of the synthetic phenotype: a possible clue to SMC differentiation in the process of atherogenesis. Atherosclerosis 144, 15-23. doi: 10.1016/S0021-9150(99)00033-7
8. Doughan, A. K., Harrison, D. G., and Dikalov, S. I. (2008). Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ. Res. 102, 488-496. doi: 10.1161/CIRCRESAHA.107.162800
9. Edwards, D. H., Li, Y., Ellinsworth, D. C., and Griffith, T. M. (2013). The effect of inorganic arsenic on endothelium-dependent relaxation: role of NADPH oxidase and hydrogen peroxide. Toxicology 306, 50-58. doi: 10.1016/j.tox.2013.01.019
10. Fronek, K., and Turner, J. D. (1980). Combined effect of cholesterol feeding and sympathectomy on the lipid content in rabbit aortas. Atherosclerosis 37, 521-528. doi: 10.1016/0021-9150(80)90059-3
11. Fu, X., Koller, S., Abd Alla, J., and Quitterer, U. (2013). Inhibition of G-protein-coupled receptor kinase 2 (GRK2) triggers the growth-promoting mitogen-activated protein kinase (MAPK) pathway. J. Biol. Chem. 288, 7738-7755. doi: 10.1074/jbc.M112.428078
12. Fukuda, D., Sata, M., Ishizaka, N., and Nagai, R. (2008). Critical role of bone marrow angiotensin II type 1 receptor in the pathogenesis of atherosclerosis in apolipoprotein E deficient mice. Arterioscler. Thromb. Vasc. Biol. 28, 90-96. doi: 10.1161/ATVBAHA.107.152363
13. Garrido, A. M., and Griendling, K. K. (2009). NADPH oxidases and angiotensin II receptor signaling. Mol. Cell. Endocrinol. 302, 148-158. doi: 10.1016/j.mce.2008.11.003
14. Gavrila, D., Li, W. G., McCormick, M. L., Thomas, M., Daugherty, A., Cassis, L. A., et al. (2005). Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 25, 1671-1677. doi: 10.1161/01.ATV.0000172631.50972.0f
15. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D., and Alexander, R. W. (1994). Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141-1148. doi: 10.1161/01.RES.74.6.1141
16. Guzik, T. J., and Harrison, D. G. (2006). Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discov. Today 11, 524-533. doi: 10.1016/j.drudis.2006.04.003
17. Hansson, G. K., and Libby, P. (2006). The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6, 508-519. doi: 10.1038/nri1882
18. Hayek, T., Attias, J., Coleman, R., Brodsky, S., Smith, J., Breslow, J. L., et al. (1999). The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc. Res. 44, 579-587. doi: 10.1016/S0008-6363(99)00239-4
19. Hayek, T., Attias, J., Smith, J., Breslow, J. L., and Keidar, S. (1998). Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. 31, 540-544. doi: 10.1097/00005344-199804000-00011
20. Hayek, T., Pavlotzky, E., Hamoud, S., Coleman, R., Keidar, S., Aviram, M., et al. (2003). Tissue angiotensin-converting-enzyme (ACE) deficiency leads to a reduction in oxidative stress and atherosclerosis: studies in ACE-knockout mice type 2. Arterioscler. Thromb. Vasc. Biol. 23, 2090-2096. doi: 10.1161/01.ATV.0000098653.74209.C6
21. Hobara, N., Gessei-Tsutsumi, N., Goda, M., Takayama, F., Akiyama, S., Kurosaki, Y., et al. (2005). Long-term inhibition of angiotensin prevents reduction of periarterial innervation of calcitonin gene-related peptide (CGRP)-containing nerves in spontaneously hypertensive rats. Hypertens. Res. 28, 465-474. doi: 10.1291/hypres.28.465
22. Keidar, S. (1998). Angiotensin, LDL peroxidation and atherosclerosis. Life Sci. 63, 1-11. doi: 10.1016/S0024-3205(98)00014-9
23. Li, H., and Förstermann, U. (2009). Prevention of atherosclerosis by interference with the vascular nitric oxide system. Curr. Pharm. Des. 15, 3133-3145. doi: 10.2174/138161209789058002
24. Lönn, M. E., Dennis, J. M., and Stocker, R. (2012). Actions of "antioxidants" in the protection against atherosclerosis. Free Radic. Biol. Med. 53, 863-884. doi: 10.1016/j.freeradbiomed.2012.05.027
25. Maor, I., Hayek, T., Coleman, R., and Aviram, M. (1997). Plasma LDL oxidation leads to its aggregation in the atherosclerotic apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 11, 2995-3005. doi: 10.1161/01.ATV.17.11.2995
26. McMurray, J., Solomon, S., Pieper, K., Reed, S., Rouleau, J., Velazquez, E., et al. (2006). The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J. Am. Coll. Cardiol. 47, 726-733. doi: 10.1016/j.jacc.2005.09.055
27. Ozer, N. K., Palozza, P., Boscoboinik, D., and Azzi, A. (1993). d-alpha-Tocopherol inhibits low density lipoprotein induced proliferation and protein kinase C activity in vascular smooth muscle cells. FEBS Lett. 322, 307-310. doi: 10.1016/0014-5793(93)81592-N
28. Pacher, P., Beckman, J. S., and Liaudet, L. (2007). Nitric oxide and peroxynitrite in health and disease. Physiol. Rev. 87, 315-424. doi: 10.1152/physrev.00029.2006
29. Piedrahita, J. A., Zhang, S. H., Hagaman, J. R., Oliver, P. M., and Maeda, N. (1992). Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 89, 4471-4475. doi: 10.1073/pnas.89.10.4471
30. Plump, A. S., Smith, J. D., Hayek, T., Aalto-Setälä, K., Walsh, A., Verstuyft, J. G., et al. (1992). Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71, 343-353. doi: 10.1016/0092-8674(92)90362-G
31. Pratico, D., Tangirala, R. K., Rader, D. J., Rokach, J., and FitzGerald, G. A. (1998). Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat. Med. 4, 1189-1192. doi: 10.1038/2685
32. Ross, R. (1999). Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126. doi: 10.1056/NEJM199901143400207
33. Schramm, A., Matusik, P., Osmenda, G., and Guzik, T. J. (2012). Targeting NADPH oxidases in vascular pharmacology. Vascul. Pharmacol. 56, 216-231. doi: 10.1016/j.vph.2012.02.012
34. Scott, T. M., Honey, A. C., Martin, J. F., and Booth, R. F. (1992). Perivascular innvervation is lost in experimental atherosclerosis. Cardioscience 3, 145-153.
35. Shvalev, V. N., Kargina-Terent'eva, R. A., and Kareeva, N. I. (1996). The phenomenon of focal sympathetic denervation of the major vessels in the development of atherosclerosis. Morfologiia 110, 102-104.
36. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., and Witztum, J. L. (1989). Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320, 915-924. doi: 10.1056/NEJM198904063201407
37. Suarna, C., Hood, R. L., Dean, R. T., and Stocker, R. (1993). Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins. Biochim. Biophys. Acta 1166, 163-170. doi: 10.1016/0005-2760(93)90092-N
38. Thomas, S. R., Leichtweis, S. B., Pettersson, K., Croft, K. D., Mori, T. A., Brown, A. J., et al. (2001). Dietary cosupplementation with vitamin E and coenzyme Q(10) inhibits atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler. Thromb. Vasc. Biol. 21, 585-593. doi: 10.1161/01.ATV.21.4.585
39. Touyz, R. M., and Schiffrin, E. L. (2001). Increased generation of superoxide by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients: role of phospholipase D-dependent NAD(P)H oxidase-sensitive pathways. J. Hypertens. 19, 1245-1254. doi: 10.1097/00004872-200107000-00009
40. Verbeuren, T. J., Simonet, S., and Herman, A. G. (1994). Diet-induced atherosclerosis inhibits release of noradrenaline from sympathetic nerves in rabbit arteries. Eur. J. Pharmacol. 270, 27-34.
41. Wassmann, S., Czech, T., van Eickels, M., Fleming, I., Böhm, M., and Nickenig, G. (2004). Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice. Circulation 110, 3062-3067. doi: 10.1161/01.CIR.0000137970.47771.AF
42. Webster, G. J., Petch, E. W., and Cowen, T. (1991). Streptozotocin-induced diabetes in rats causes neuronal deficits in tyrosine hydroxylase and 5-hydroxytryptamine specific to mesenteric perivascular nerves and without loss of nerve fibers. Exp. Neurol. 113, 53-62. doi: 10.1016/0014-4886(91)90146-4
43. Young, P. P., Modur, V., Teleron, A. A., and Ladenson, J. H. (2005). Enrichment of genes in the aortic intima that are associated with stratified epithelium: implications of underlying biomechanical and barrier properties of the arterial intima. Circulation 111, 2382-2390. doi: 10.1161/01.CIR.0000164235.26339.78
44. Yusuf, S., Sleight, P., Pogue, P., Bosch, J., Davies, R., and Dagenais, G. (2000). Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N. Engl. J. Med. 342, 145-153. doi: 10.1056/NEJM200001203420301
45. Zafari, A. M., Ushio-Fukai, M., Akers, M., Yin, Q., Shah, A., Harrison, D. G., et al. (1998). Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 32, 488-495. doi: 10.1161/01.HYP.32.3.488
46. Zhao, H., Kalivendi, S., Zhang, H., Joseph, J., Nithipatikom, K., Vasquez-Vivar, J., et al. (2003). Superoxide reacts with hydroethidine but forms a fluorescent product that is distinctly different from ethidium: potential implications in intracellular fluorescence detection of superoxide. Free Radic. Biol. Med. 34, 1359-1368. doi: 10.1016/S0891-5849(03)00142-4
47. Zukowska-Grojec, Z., Karwatowska-Prokopczuk, E., Rose, W., Rone, J., Movafagh, S., Ji, H., et al. (1998). Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 83, 187-195. doi: 10.1161/01.RES.83.2.187